tbuckley/cabot-search huggingface dataset:
Abstract 822: PureQuant Methylation Assay for the accurate quantification of immune cell populations
Authors: Suman Pradhan, Carl Dargitz, Jerry Guzman, Uma Lakshmipathy
Journal: Cancer Research (2019)

Abstract A key challenge during the development and manufacturing of cell based immunotherapies is the reliable estimation of cell purity. Current flow cytometric methods, while effective for the detection of surface antigens such as CD8 that positively identifies Cytotoxic T lymphocytes, are not ideal for intracellular markers used to positively identify Regulatory T (Treg) cells and T Helper 17 (Th17) cells. Additionally, characterization methods that utilize live cells pose a challenge in large scale GMP manufacturing environments due to complicated logistics, limited throughput and difficulty in standardization. Therefore, there is an emerging need for alternative assay methods that address some of these challenges. Here, we introduce our newly developed PureQuant™ Assays that specifically measure the unique DNA methylation status of specific immune cell types. Assays were developed specifically for Cytotoxic T Cells, Regulatory T cells and T helper 17 cells by detecting methylation status of CD8, FoxP3 and IL17A, respectively, via qPCR of bisulfite converted genomic DNA. These assays are robust with minimal sample requirement, utilizing fresh/frozen cells or isolated gDNA. Results are represented as a percentage of the total cell population similar to flow cytometry based methods. Comparison of the two methods for surface markers such as CD8 show comparable results. Our results demonstrate that this method which combines accuracy, low sample requirement and flexibility, is an ideal measurement system for confirmation of T cell identity and purity that is critical for cell therapy research and development. Citation Format: Suman Pradhan, Carl Dargitz, Jerry Guzman, Uma Lakshmipathy. PureQuant Methylation Assay for the accurate quantification of immune cell populations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 822.
Efficacy of antidepressants in irritable bowel syndrome: an updated systematic review and meta-analysis controlling for depression
Authors: A. C. Ford, N. J. Talley, P. Moayyedi
Journal: Gut (2011)

<h3>Introduction</h3> Antidepressants may be effective for the treatment of irritable bowel syndrome, but some experts are sceptical, and effect of co-existent depression has not been controlled for in previous meta-analyses. We updated a previous systematic review to estimate their efficacy in the treatment of IBS and examine this issue. <h3>Methods</h3> MEDLINE, EMBASE and the Cochrane Controlled Trials Register were searched (up to November 2010) to identify randomised controlled trials (RCTs) comparing antidepressants with placebo in adult IBS patients. Subjects were required to be followed up for at least 1 week, and studies had to report either a global assessment of IBS symptom cure or improvement, or abdominal pain cure or improvement, after completion of therapy. Data were extracted as intention-to-treat analyses with drop-outs assumed to be treatment failures, and pooled using a random effects model. Effect of antidepressants compared to placebo was reported as the relative risk (RR) of remaining symptomatic, with a 95% CI. Trials that screened for and excluded depressed individuals were pooled separately in a subgroup analysis. <h3>Results</h3> 16 RCTs were eligible for inclusion, including 1022 patients, 554 of whom received antidepressants and 468 placebo. Nine RCTs used tricyclic antidepressants (TCAs), six RCTs selective serotonin reuptake inhibitors (SSRIs), and one RCT both. There were 242 (43.7%) patients assigned to antidepressant therapy with persistent or unimproved IBS symptoms following therapy, compared to 314 (64.9%) allocated to placebo (RR of IBS symptoms persisting = 0.67; 95% CI 0.56 to 0.78). When the 10 RCTs of TCAs were pooled, 166 (43.9%) of 378 had persistent symptoms, compared to 189 (62.2%) of 304 receiving placebo (RR = 0.70; 95% CI 0.60 to 0.83). In the five RCTs of SSRIs 76 (43.2%) of 176 patients allocated to SSRIs had persistent symptoms, compared to 125 (69.4%) of 180 placebo patients (RR = 0.63; 95% CI 0.44 to 0.91). When only the four RCTs that screened for and excluded depressed individuals were included in the analysis RR of symptoms persisting was 0.73 (95% CI 0.47 to 1.15), compared with a RR of 0.65 (95% CI 0.55 to 0.78) in the other 12 trials. However, this difference was not statistically significant (Cochrane Q = 0.64). <h3>Conclusion</h3> Evidence continues to accumulate for the efficacy of antidepressants in the treatment of IBS. However, part of their beneficial effect may stem from the treatment of co-existent depression. More RCTs examining their efficacy in non-depressed IBS patients are required to clarify this issue.
Apparent right midlung mass in a dyspneic man
Authors: R. D. Mountain
Journal: JAMA (1983)

<h3>History</h3> A 61-year-old man was admitted to the hospital with a ten-day history of increasing dyspnea on exertion, orthopnea, fatigue, and increasing peripheral edema. His history indicated long-standing congestive cardiomyopathy and chronic atrial fibrillation. The patient had a 50-pack-year smoking history but no notable occupational exposures. Current medications included digoxin, furosemide, and warfarin sodium; however, the patient had a history of medical noncompliance. His physical examination showed a BP of 92/66 mm Hg, an irregularly irregular pulse rate of 120 beats per minute, elevated jugular venous pressure, bibasilar rales, a prominent third heart sound, and symmetrical pitting edema of the knees. A gated blood pool cardiac scan showed a left ventricular ejection fraction of 21%. Posteroanterior (Fig 1) and lateral (Fig 2) roentgenograms of the chest were obtained. <h3>Diagnosis</h3> "Pseudotumor" (interlobar effusion) of the superior accessory fissure, right lower lobe. The admission posteroanterior chest roentgenogram (Fig 1) showed cardiomegaly, bilateral
L'endoscopie assistée par ballonnet facilite la dissection sous-muqueuse endoscopique des tumeurs superficielles superficielles difficiles du côlon proximal
Journal: Endoscopy (2018)

Les résections endoscopiques a fortiori les dissections sous muqueuses (DSM) du colon droit peuvent être gênées lorsque la progression est difficile ou par les mouvements péristaltiques.
Medicaid at 30
Authors: Diane Rowland
Journal: JAMA (1995)

Since its enactment in 1965, Medicaid has been on the front lines in meeting the health needs of our nation's most vulnerable populations. It has evolved from the companion legislation to Medicare that provided health financing to states for coverage of their welfare population, to a program that now finances health and long-term care services for one in eight Americans. In its 30 years, Medicaid has enabled millions of low-income Americans to gain access to needed health services, helping to close the gaps in care between the poor and nonpoor, ease financial burdens, and provide a safety net for the most needy Americans.<sup>1</sup> Today, Medicaid's role as a health insurer and safety net for vulnerable Americans is visible throughout the health care system. Medicaid finances care for one in four American children, pays for one third of the nation's births, assists 60% of people living in poverty, pays for
Magnesium Concentration
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A population-based study of metastatic colorectal cancer (mCRC) in people age 80 or older: Findings from the South Australian Clinical Registry (SACR) for mCRC.
Authors: C. Beeke, K. Jain, T. J. Price, R. Padbury, D. Roder, G. P. Young, M. Ly, M. A. Khattak, A. Richards, A. R. Townsend, C. S. Karapetis
Journal: Journal of Clinical Oncology (2011)

9082 Background: Life expectancy is increasing and more patients (pts) with mCRC are presenting at an advanced age (>80). Optimal management approach for this group of pts is not well defined as they are under-represented in clinical trials. Methods: The SACR for mCRC collects data on mCRC pts diagnosed after 1/2/2006. We examined cancer characteristics, treatment and outcome for pts aged >80 yrs. Comparison was made with pts <80 yrs. Results: Data from 1,878 eligible mCRC pts has been entered to date. 559 (30%) of these pts were aged ≥ 80. Key pt characteristics and treatments are reported in the table. Grade 3 differentiation was reported in lower proportion of pts ≥80 yrs than the younger group (18.4 % vs. 26.3 %, p < 0.001). Only 25% of pts >80 received chemotherapy (CT). Of these, 67% received single agent CT (mostly capecitabine) while 33% received combination CT as first line treatment. In comparison, 69% of pts <80 had CT, 75% of which received combination and 25% single agent (majority capecitabine) as their first line CT. Pts ≥ 80 had fewer liver resections, were less likely to receive radiotherapy or monoclonal antibodies and had lower recruitment in clinical trials. Median survival (MS) was 7.9 mths for >80 yrs vs. 19.6 mths for <80 yrs; p < 0.001. MS for pts treated with CT was 20 mths for >80 and 23 mths for <80, p = 0.127. Pts without any treatment had a poor survival regardless of their age (MS 2.9 mths >80 yrs vs. 3.4 mths <80 yrs). Conclusions: Older pts (≥ 80 yrs) were less likely to receive intervention for their mCRC and had poorer survival. However, survival for selected elderly pts, who received CT, was similar to those <80, despite most receiving single agent therapy. Patient characteristics and treatments. (<80 yrs) n = 1,319 (≥80 yrs) n = 559 Median age (range) 67 (17-79) 85 (80–105) Sex—M/F 799 (60%)/520 (40%) 272 (49%)/287 (51%) Synchronous primary 867 (66%) 339 (61%) Rectal primary 364 (28%) 113 (20%) Liver only metastatic site 540 (41%) 199 (36%) ≥3 metastatic sites 112 (8.5%) 48 (9%) Liver resections 213 (16%) 34 (6%) Surgery 753 (57%) 232 (41.5%) Monoclonal antibody 169 (13%) 11 (2%) Radiotherapy 263 (20%) 42 (7.5%) No treatment 156 (12%) 221 (39.5%)
Council on Physical Therapy
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Reply
Authors: Pascal Pommier, Sylvie Chabaud
Journal: Journal of Clinical Oncology (2008)

dose was used for many patients (66 Gy), the pelvic field was slightly smaller than the one used in RTOG 94-13 (superior border was only up to S1/S2), and the posthoc calculated risk of nodal positivity by the Roach formula was less than 15% for more than half the patients.Yet despite these potential limitations, negative results of two large prospective randomized trials make it difficult to justify the uniform use of pelvic fieldWe admire and are grateful to the authors of both studies for designing and conducting these landmark trials to answer a very important clinical question.Since both randomized trials failed to demonstrate an advantage to treating the pelvic lymph nodes when compared with treatment of the prostate and seminal vesicles alone.Therefore, evidence to justify the use of the pelvic field is lacking for men with intermediate-and high-risk localized prostate cancer.An additional randomized study is needed in men with T3/T4 and Gleason 4ϩ3 or higher prostate cancer, who represent those with highest risk locally advanced disease and are similar to the patients in RTOG 8610, 8531, and 9202, and EORTC 22863, to test the hypothesis that the use of the pelvic field contributed to the benefit observed in those studies.
Long-term follow-up results of a randomized drug abuse prevention trial in a white middle-class population
Authors: G. J. Botvin
Journal: JAMA (1995)

<h3>Objective.</h3> —To evaluate the long-term efficacy of a school-based approach to drug abuse prevention. <h3>Design.</h3> —Randomized trial involving 56 public schools that received the prevention program with annual provider training workshops and ongoing consultation, the prevention program with videotaped training and no consultation, or "treatment as usual" (ie, controls). Follow-up data were collected 6 years after baseline using school, telephone, and mailed surveys. <h3>Participants.</h3> —A total of 3597 predominantly white, 12th-grade students who represented 60.41% of the initial seventh-grade sample. <h3>Intervention.</h3> —Consisted of 15 classes in seventh grade, 10 booster sessions in eighth grade, and five booster sessions in ninth grade, and taught general "life skills" and skills for resisting social influences to use drugs. <h3>Measures.</h3> —Six tobacco, alcohol, and marijuana use self-report scales were recoded to create nine dichotomous drug use outcome variables and eight polydrug use variables. <h3>Results.</h3> —Significant reductions in both drug and polydrug use were found for the two groups that received the prevention program relative to controls. The strongest effects were produced for individuals who received a reasonably complete version of the intervention—there were up to 44% fewer drug users and 66% fewer polydrug (tobacco, alcohol, and marijuana) users. <h3>Conclusions.</h3> —Drug abuse prevention programs conducted during junior high school can produce meaningful and durable reductions in tobacco, alcohol, and marijuana use if they (1) teach a combination of social resistance skills and general life skills, (2) are properly implemented, and (3) include at least 2 years of booster sessions. (<i>JAMA</i>. 1995;273:1106-1112)
Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.
Authors: Thomas E. Witzig, Julie M. Vose, Timothy D. Moore, Craig B. Reeder, Craig E. Cole, Glen Justice, Henry P. Kaplan, Michael Voralia, Dennis Pietronigro, Kenichi Takeshita, Annette Ervin-Haynes, Jerome B. Zeldis, Peter H. Wiernik
Journal: Blood (2007)
Editors, Contents, Cover details
Authors: Arturo Hernandez, Ping Li, Jubin Abutalebi, Morris Moscovitch, Lynn Nadel, Daniel Barry, Eleanor Maguire, Judith Holler, Stephen Levinson, Avinash Vaidya, Maia Pujara, Michael Petrides, Elisabeth Murray, Lesley Fellows, Daniel Kaiser, Genevieve Quek, Radoslaw Cichy, Marius Peelen, Lindsey Drayton, Jessica Miles, Rolf Van Der Sanden, Patrick Scheffmann, Ralph Adolphs, Renee Baillargeon, Nick Chater, Peter Dayan, Stanislas Dehaene, Daniel Dennett, Yadin Dudai, Andreas Engel, Martha Farah, Angela Friederici, Okihide Hikosaka, Ray Jackendoff, Philip Johnson-Laird, Nancy Kanwisher, Christof Koch, Marta Kutas, Nikos Logothetis, James Mcclelland, Earl Miller, Elizabeth Phelps, Russell Poldrack, Marcus Raichle, Trevor Robbins, Anthony Wagner, Vincent Walsh
Journal: Trends in Cognitive Sciences (2019)
Outdoor allergens.
Authors: H A Burge, C A Rogers
Journal: Environmental Health Perspectives (2000)

Outdoor allergens are an important part of the exposures that lead to allergic disease. Understanding the role of outdoor allergens requires a knowledge of the nature of outdoor allergen-bearing particles, the distributions of their source, and the nature of the aerosols (particle types, sizes, dynamics of concentrations). Primary sources for outdoor allergens include vascular plants (pollen, fern spores, soy dust), and fungi (spores, hyphae). Nonvascular plants, algae, and arthropods contribute small numbers of allergen-bearing particles. Particles are released from sources into the air by wind, rain, mechanical disturbance, or active discharge mechanisms. Once airborne, they follow the physical laws that apply to all airborne particles. Although some outdoor allergens penetrate indoor spaces, exposure occurs mostly outdoors. Even short-term peak outdoor exposures can be important in eliciting acute symptoms. Monitoring of airborne biological particles is usually by particle impaction and microscopic examination. Centrally located monitoring stations give regional-scale measurements for aeroallergen levels. Evidence for the role of outdoor allergens in allergic rhinitis is strong and is rapidly increasing for a role in asthma. Pollen and fungal spore exposures have both been implicated in acute exacerbations of asthma, and sensitivity to some fungal spores predicts the existence of asthma. Synergism and/or antagonism probably occurs with other outdoor air particles and gases. Control involves avoidance of exposure (staying indoors, preventing entry of outdoor aerosols) as well as immunotherapy, which is effective for pollen but of limited effect for spores. Outdoor allergens have been the subject of only limited studies with respect to the epidemiology of asthma. Much remains to be studied with respect to prevalence patterns, exposure and disease relationships, and control.
Transplantation, 1963
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prophylaxis with norfloxacin is not associated with multi-drug resistant bacterial infections
Authors: Sebastián Marciano, Maria Nelly Gutierrez Acevedo, Sabrina Barbero, Lorena Del Carmen Notari, Marina Agozino, Jose Luis Fernandez, Maria Margarita Anders, Nadia Grigera, Florencia Antinucci, Orlando Orozno Ganem, Maria Dolores Murga, Daniela Perez, Ana Palazzo, Liria Martinez Rejtman, Ivonne Giselle Duarte, Julio Vorobioff, Victoria Trevizan, Sofía Bulaty, Fernando Bessone, José Daniel Bosia, Silvia Mabel Borzi, Teodoro E. Stieben, Adriano Masola, Sebastian Eduardo Ferretti, Diego Arufe, Ezequiel Demirdjian, Maria Pia Raffa, Cintia Elizabet Vazquez, Pablo Ruiz, José Emanuel Martínez, Leandro Alfredo Heffner, Andrea Odzak, Melisa Dirchwolf, Astrid Smud, Diego Giunta, Manuel Mendizabal, Carla Bellizzi, Ana Martinez, Jesica Tomatis, Andres Bruno, Agñel Ramos, Josefina Pages, Silvina Tevez, Guillermo R. Fernandez, Adrian Gadano
Journal: Journal of Hepatology (2020)
GASTRIC SECRETION AND OTHER DIGESTIVE FACTORS IN ROSACEA
Authors: SIBYL RENEE EASTWOOD
Journal: British Journal of Dermatology (1928)

Journal Article GASTRIC SECRETION AND OTHER DIGESTIVE FACTORS IN ROSACEA Get access SIBYL RENEE EASTWOOD, M.A., D.M., B.Ch.Oxon., M.R.C.P.Lond. SIBYL RENEE EASTWOOD, M.A., D.M., B.Ch.Oxon., M.R.C.P.Lond. Assistant Physician, South London Hospital; late Clinical Assistant in Department of Skin Diseases, University College Hospital Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology and Syphilis, Volume 40, Issue 4, 1 April 1928, Pages 148–167, https://doi.org/10.1111/j.1365-2133.1928.tb12112.x Published: 01 April 1928
Effectiveness of Disease and Injury Prevention
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal